MAYWOOD, N.J., May 16, 2011 /PRNewswire/ — New Jersey Center for Prostate Cancer & Urology is among the first sites in the nation to treat advanced prostate cancer patients with PROVENGE (sipuleucel-T), the first in a new therapeutic class known as autologous cellular immunotherapies. PROVENGE was approved by the U.S. Food and Drug Administration (FDA) for the treatment of men with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer and is made by Dendreon Corporation.

“PROVENGE is a revolutionary new treatment that may lead to similar personalized therapies in other cancer types,” said Dr. Vincent Lanteri of NJ Center for Prostate Cancer & Urology. “We are pleased to have a new option to offer our patients and to be selected as one of the first facilities treating men with this important new therapy.”

“PROVENGE allows patients to use their own cells to help fight cancer,” said Dr. Michael Esposito. “Patients with advanced prostate cancer now have a new option to prolong their lives. I’m very excited about this and have high hopes for it.”

PROVENGE is an autologous (made from a patient’s own immune cells) cellular immunotherapy designed to stimulate a patient’s immune system to identify and target prostate cancer cells. Each dose is manufactured specifically for each patient using his immune cells.

Individuals interested in learning whether PROVENGE is an appropriate treatment option should contact New Jersey Center for Prostate Cancer & Urology 201-487-8866 or call 1-877-336-3736.

About New Jersey Center for Prostate Cancer & Urology

The doctors of New Jersey Center for Prostate Cancer and Urology are undisputed experts in the field and have been recognized as ‘Top Doctors’ by New Jersey Monthly and New York Magazine and selected by Castle Connolly as ‘Top Doctors for Cancer’ in the country. With locations in Northern and Central New Jersey, the practice offers patients needing prostate cancer or urological treatment easy access to state-of-the-art urological care close to home. Offices are located at 255 W. Spring Valley Avenue, Maywood, NJ, at Holy Name Medical Center 718 Teaneck Road, Teaneck NJ, and at Monmouth Medical Center, 255 Third Avenue, Long Branch, NJ. For more information about New Jersey Center for Prostate Cancer and Urology call (201) 487-8866 or visit www.RoboticUrology.com.

SOURCE New Jersey Center for Prostate Cancer & Urology